• Bio-Nano Sensium Technologies will exploit Toumaz AMx™ advanced mixed signal technology
• Patented ultra-low power technology utilizes sub-threshold CMOS analog combined with digital control
• Intelligent sensors target implanted medical electronics
Abingdon, United Kingdom, March 15, 2005 - Toumaz Technology Ltd and Advance Nanotech, Inc., announce a joint venture to bridge the gap between nanosystems and the macroscopic world.
Bio-Nano Sensium Technologies, the name of the joint venture, will utilize an intelligent, ultra-low power sensor interface, incorporating wireless communication, to create bio-nano sensors that can be implanted within the body to diagnose and treat a wide variety of medical conditions. The development effort will focus on the information and communication technology systems necessary for these sensors to interact with their surrounding environment.
Development of the sensor will leverage the many years of research in ultra-low power circuits and systems at Imperial College of Science, Technology and Medicine, London now exploited by Toumaz Technology Ltd, in their proprietary Advanced Mixed Signal “AMx™” technology and wireless transceiver devices. The Bio-Nano Sensium will be capable of power consumption orders of a magnitude lower than current state-of-the-art microprocessors. This nano-power mode of operation is vital to the longer lifetimes, reliability, and stability required in biosensors, especially those that are implanted within the body. The Bio-Nano Sensium will be based on industry-standard Complementary Metal Oxide Semiconductor (CMOS) technology so that not only will it have superior functional features to other devices but also be capable of low-cost production.
Keith Errey, CEO of Toumaz Technology, stated, "We are very excited about this joint venture. Toumaz has worked over the past 4 years to develop a patented, low-power platform technology and we are very pleased to be working with Advance Nanotech to commercialize its use for the next generation of medical devices in the high-value bio-nano sector."
Commenting on the joint venture, Magnus Gittins, CEO of Advance Nanotech, Inc., said, "The Bio-Nano Sensium will play a pivotal role in enabling truly personalized healthcare, where continuous diagnosis can be matched to a treatment program tailored to meet the needs of the individual – all within a small, implantable medical device. Previous investments made by Toumaz Technology into the platform technologies, which make the Bio-Nano Sensium possible, take us well into the commercialization process."
About Toumaz Technology Ltd.
Toumaz Technology Limited is a developer of advanced RF, analogue and mixed signal semiconductors. The focus of the business is low power devices based on the company’s proprietary AMx™ (Advanced Mixed Signal) technology which addresses the needs of lower power consumption for mobile and wirelessly connected systems.
About Advance Nanotech Inc
Advance Nanotech, Inc. (``Advance'') commercializes innovative nanotechnology. Operating in three areas, electronics, biopharma and materials, Advance leverages relationships with financial and development resources to enable a product focused fast-track commercialization of nanotechnology. Advance has established relationships with academic institutions throughout the world that are at the forefront of nanotechnology research and development. Advance's objective is to invest in patented innovation to bridge early stage product development with valuable markets. Advance Nanotech is quoted on the Over-The-Counter Bulletin Board under the symbol "AVNA.OB." For more information on Advance Nanotech, visit the company's website at http://www.advancenanotech.com.
resonates PR for Toumaz Technology
Nicky Davis +44 (0) 7747 017654
Advance Nanotech, Inc. – New York
Stephanie Interbartolo 212-332-4386
Advance Nanotech, Inc. – London
Charlotte Ramelli +44 (0) 207 451 2466